Pacira Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Biosciences, Inc. on June 19, 2019. The filing discloses the appointment of a new executive officer and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation details:
- Base Salary: $520,000 per year for the new President.
- Annual Incentive Target: 50% of the annual base salary.
- Equity Grant: 200,000 stock options with a 10-year term.
- Vesting Schedule: 25% on the first anniversary, with the remainder vesting in equal quarterly installments over the subsequent three years.
Material Changes
On June 19, 2019, the Company appointed Max Reinhardt as President, effective immediately. Mr. Reinhardt previously served as Vice President of Marketing for DePuy Synthes (Johnson & Johnson) since March 2016. This appointment represents a significant change in the Company's executive leadership.
Outlook, Risks, and Contingencies
The filing outlines specific severance and change of control provisions in the new Employment Agreement:
- Termination without Cause/Good Reason: Entitles the executive to nine months of salary continuation, 12 months of health insurance, and accelerated vesting of options that would have vested during the nine-month period.
- Change of Control Provisions: If termination occurs within 30 days prior to or 12 months following a change of control, the executive is entitled to 12 months of salary continuation, a bonus equal to 50% of base salary, 12 months of health insurance, and immediate vesting of all outstanding unvested options.
Investor Verification Checklist
- Verify the total potential payout under the severance and change of control provisions.
- Confirm the impact of the 200,000 stock option grant on existing shareholder dilution.
- Review the press release (Exhibit 99.1) for strategic rationale behind the leadership change.
- Check subsequent filings for any changes to the vesting schedule or compensation terms.